Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rHSC-DIPGVax with Checkpoint Blockade in Pediatric DIPG and DMG
NCT04943848Phase 1Recruiting
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Start
- Jan 2022
- Primary completion
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label trial of rHSC-DIPGVax in diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) (4 arms), sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Primary endpoints: Dose Limiting Toxicities of rHSC-DIPGVax at 28 days, Dose Limiting Toxicities of rHSC-DIPGVax plus BALSTILIMAB at 28 days and 1 more. Started Jan 2022; status: recruiting.
02
Drugs
rHSC-DIPGVax
03
Conditions
diffuse intrinsic pontine glioma (DIPG)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT04943848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943848.